Briviact generic date?

What is the timeline for the generic version of Briviact?

Briviact, an antiepileptic medication, has been a subject of interest for generic companies. According to [1] DrugPatentWatch.com, the patent for Briviact, owned by UCB Inc. and Eisai Co., Ltd., is set to expire in 2026.

When does exclusivity expire?

UCB Inc. and Eisai Co., Ltd. filed the New Drug Application (NDA) for Briviact with the FDA in 2016. The original approval was granted in 2016, and as per the FDA's 505(b)(2) regulatory pathway, the patent expiration date for Briviact is set to be in August 2026 [2]. This means that generic manufacturers can file an Abbreviated New Drug Application (ANDA) with the FDA as early as August 2025.

How will a generic version of Briviact impact the market?

The introduction of a generic Briviact could lead to cost savings for patients and insurers. Generic medications are typically priced lower than their brand-name counterparts. However, it is essential to note that the generic version may not be identical in composition or formulation to the original Briviact.

What should patients and healthcare providers know?

As the generic version of Briviact becomes available, patients and healthcare providers should be aware of potential differences in the generic formulation. It is crucial to consult with a healthcare provider before switching from Briviact to a generic version.

Sources:

[1] DrugPatentWatch.com
[2] U.S. FDA

List of sources:

1. DrugPatentWatch.com [https://drugpatentwatch.com/brand/briviact]
2. U.S. FDA [https://www.fda.gov]